Created at	Source	Raw Value	Validated value
Oct. 1, 2022, 6:30 a.m.	usa	Part1, Primary immunogenicity;Part1, Primary Safety;Part2, Primary immunogenicity	Part1, Primary immunogenicity;Part1, Primary Safety;Part2, Primary immunogenicity
Oct. 22, 2021, 10 a.m.	usa	Efficacy at Phase III study(Period 1);Immunogenicity at Phase II study;Safety at Phase III study(Period 2);Safety at Phase III studyPeriod 2;Safety at Phase II study;Safety at Phase II study;Safety at Phase II study	Efficacy at Phase III study(Period 1);Immunogenicity at Phase II study;Safety at Phase III study(Period 2);Safety at Phase III studyPeriod 2;Safety at Phase II study;Safety at Phase II study;Safety at Phase II study